Pulse Edge’s Post

Paul Bravetti (PharmD, HEC Paris) is a strategic executive with a particular interest in scientific innovation and entrepreneurial adventures. He joined Brenus Pharma in 2020 and became Chief Executive Officer in 2022 with a clear mission, vision, and leadership to address current treatment limitations and make a significant impact for cancer patients. Thanks to his international experience in major pharmaceutical companies, he has successfully led the launches of therapeutics in immuno-oncology and biomolecular diagnostics across Europe and Asia. This experience has shaped his understanding of the biopharmaceutical industry and its unmet needs. Meet Paul Bravetti @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

🎗️ 𝐎𝐯𝐚𝐫𝐢𝐚𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐇𝐨𝐩𝐞 𝐢𝐧 𝐖𝐨𝐦𝐞𝐧'𝐬 𝐇𝐞𝐚𝐥𝐭𝐡 The Ovarian Cancer Drugs Market is evolving rapidly as researchers and pharmaceutical companies focus on innovative treatments to address this challenging condition. With advancements in targeted therapies and immuno-oncology, there’s renewed hope for improving survival rates and enhancing the quality of life for patients. 𝗖𝗹𝗶𝗰𝗸 𝗵𝗲𝗿𝗲 𝘁𝗼 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝘁𝗵𝗲 𝗳𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝗽𝗼𝗿𝘁: https://lnkd.in/g2GP48VV 🔑 Market Drivers: 1️⃣ Rising Incidence of Ovarian Cancer: Increased prevalence driving demand for effective therapies. 2️⃣ Precision Medicine: Emergence of biomarker-based treatments tailored to individual patients. 3️⃣ Regulatory Approvals: Accelerated pathways bringing innovative drugs to market faster. 4️⃣ Collaborative Research: Partnerships between biotech firms and research institutions fostering innovation. 🚀 Emerging Trends: Combination Therapies: Synergizing drugs for improved efficacy and reduced resistance. AI in Drug Development: Accelerating discovery and clinical trial efficiencies. Patient-Centric Approaches: Emphasis on quality of life and management of side effects. #Company Bristol Myers Squibb Eli Lilly and Company GlaxoSmithKline Janssen Pharmaceuticals Novogene Genentech Aetera Zenteris Boehringer Ingelheim Roche #Type Surgery Chemotherapy Radiation Biological Therapy #Applications Hospital Clinics Others 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐁𝐮𝐲 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/ghDjkr-i ✅ 𝐅𝐨𝐥𝐥𝐨𝐰-Stringent Datalytics - Healthcare #OvarianCancer #Oncology #TargetedTherapies #PrecisionMedicine #PharmaceuticalInnovation

🔬 Tom's Top 3 - Ep. 2! 🚀 What's happened over the last week... Follow along for the updates! 👉 Q1's Fierce Biotech Layoff Analysis! In 2024, the biotech sector faces ongoing challenges, with persistent layoffs reflecting the aftermath of the 2023 bear market. Despite hurdles, companies remain resilient, navigating uncertain conditions and clinical trial setbacks. 💡 Spanish pharmaceutical giant Ferrer makes waves in AI-driven neuroscience research with a $122 million deal securing rights to Verge Genomics' clinical-stage ALS therapy. This strategic move underscores Ferrer's commitment to innovative treatments, positioning them to address critical medical needs and fill pipeline gaps. 🌟 Ipsen Pharmaceuticals enters the ADC race with a $900 million deal, marking a significant milestone in oncology research. This strategic move highlights Ipsen's dedication to advancing cancer treatment, positioning them alongside industry leaders targeting the ROR1 tumor antigen. Their bold move could be reshaping the competitive landscape in oncology research and development. Join us in celebrating these groundbreaking advancements in the biotech industry! 💼🔬 #Biotech #Innovation #Healthcare #Pharmaceuticals #AI #Oncology #ALS #ADCs

🔍 In the 3rd Episode of our Season 2 of Pipeline Analysis series, we delve into AbbVie’s Q2 2024 performance. Here are the key highlights: 💰 Net Revenue: AbbVie reported an impressive net revenue of $14.46 billion. 🌟 Key Assets: AbbVie’s top revenue generators are Humira and Skyrizi, both within the immunology portfolio 📊 Portfolio Breakdown: Immunology portfolio: $6.97 billion Neuroscience portfolio: $2.16 billion Oncology portfolio: $1.63 billion Aesthetics portfolio: $1.4 billion 🧪 R&D Investment: AbbVie allocated $1.9 billion for research and development, driving innovation and growth. 🌐 Strategic Moves: AbbVie completed the acquisition of Landos Biopharma and also acquiring Celsius Therapeutics, reinforcing its position in the industry. Stay tuned to RAS LifeScience Solutions for more profound insights and updates. #Abbvie #PipelineAnalysis #Innovation #Healthcare #Biopharmaceuticals #FutureOfMedicine

🔥🚀 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐌&𝐀 𝐄𝐱𝐩𝐥𝐨𝐬𝐢𝐨𝐧 𝐢𝐧 2024! 🚀🔥 🤔 Did you know the number of biopharma M&A deals has more than doubled in Q1 of 2024 compared to last year? From 6 to 13, totaling 47 in the last twelve months! 📈 🎉 𝐁𝐢𝐠 𝐌𝐨𝐯𝐞𝐬 𝐢𝐧 𝐁𝐢𝐠 𝐏𝐡𝐚𝐫𝐦𝐚: • AstraZeneca shakes up oncology with deals for Fusion Pharmaceuticals & Gracell Biotechnologies! 🧬 • Merck Life Science acquires T-cell magic from Harpoon Therapeutics! 🎯 🌟 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤’𝐬 𝐇𝐞𝐚𝐝𝐥𝐢𝐧𝐞𝐫𝐬: • Takeda could spend up to $1.2 billion on a new cancer fighter with Kumquat Biosciences Inc.! 🛡️ • Boehringer Ingelheim and Ochre Bio tackle liver disease with a billion-dollar RNA therapy bet! 🧪 • Ipsen is investing $1.8 billion in neuroscience R&D with Skyhawk Therapeutics! 🧠 🌐 With Big Pharma's unwavering interest, 2024 is set to be a groundbreaking year for biotech M&A. What’s your take? Could this be the boost we've been waiting for in innovation and competition? 💡 #Biotech #MergersAndAcquisitions #Innovation #PharmaIndustry #FutureOfPharma

Our CEO Michael Nally spoke at MassBio's State of Possible Conference with Barry Greene of Sage Therapeutics, Sharon Cunningham of Shorla Oncology, and Daphne Zohar of Seaport Therapeutics, moderated by Douglas Banks of Boston Business Journal. The panel explored Massachusetts' success in the life science industry—a story of innovation and resilience. These leaders discussed how they have survived and thrived through significant challenges. In a blog entry for MassBio, Mike notes: "By spearheading the transition from trial-and-error to programable, precision-based drug development, Massachusetts is reshaping the future of healthcare to better serve patients, the ecosystem, and the economy." Learn more about the panel, including a replay: https://lnkd.in/eHanbnQF #GenerativeAI I #ProteinEngineering 

𝐌𝐮𝐧𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐡𝐚𝐬 𝐞𝐧𝐭𝐞𝐫𝐞𝐝 𝐚 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐆𝐒𝐊 Muna Therapeutics Muna Therapeutics has announced a strategic alliance with GSK GSK to accelerate the development of novel treatments for Alzheimer's disease. This multi-year collaboration will leverage Muna's MiND-MAP platform, which utilizes spatial transcriptomics to analyze brain samples from Alzheimer's patients and other groups, aiming to identify and validate new drug targets and treatment pathways. Under the agreement, GSK secures an option to multiple high-value, validated Alzheimer's-relevant targets for drug discovery, development, and commercialization. Muna will receive an upfront payment of €33.5 million and is eligible for up to €140 million per target in milestone payments, along with tiered royalties on net sales of resulting products. Muna will lead the expansion of the MiND-MAP dataset and the identification and validation of new targets, while GSK will handle drug development, preclinical activities, clinical development, manufacturing, and commercialization. This partnership aims to transform drug discovery for neurodegenerative diseases, offering new hope to millions of patients worldwide. #AlzheimersResearch #NeurodegenerativeDiseases #BiotechCollaboration #DrugDiscovery

𝐓𝐡𝐞 𝐑𝐢𝐬𝐞 𝐨𝐟 𝐍𝐚𝐧𝐨𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬: 𝐀 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐨𝐢𝐬𝐞𝐝 𝐟𝐨𝐫 𝐆𝐫𝐨𝐰𝐭𝐡 The global #nanomedicine_therapeutics_market is experiencing a surge in growth, projected to reach a staggering CAGR of 12.5% by 2028! This exciting field holds immense potential to revolutionize healthcare by utilizing nanoparticles for targeted drug delivery and improved treatment efficacy. 𝐆𝐞𝐭 𝐚 𝐂𝐨𝐦𝐩𝐥𝐢𝐦𝐞𝐧𝐭𝐚𝐫𝐲 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐭𝐡𝐞 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (2024-30)- https://lnkd.in/gRMKWmeX 𝐊𝐞𝐲 𝐟𝐚𝐜𝐭𝐨𝐫𝐬 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐫𝐨𝐰𝐭𝐡 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: ✅The increasing demand for targeted cancer therapies: #Nanomedicines offer a promising approach to deliver drugs directly to cancer cells, minimizing side effects on healthy tissues. ✅Growing awareness of nanomedicine's potential in various #therapeutic areas: Beyond cancer, nanomedicine holds promise for treating infectious diseases, neurodegenerative disorders, and more. 𝐇𝐨𝐰𝐞𝐯𝐞𝐫, 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐚𝐥𝐬𝐨 𝐞𝐱𝐢𝐬𝐭: ✅Concerns regarding nanotoxicity need to be addressed through rigorous research and development. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬- Johnson & Johnson, Bristol Myers Squibb, Ipsen, GSK, Arrowhead Pharmaceuticals, Nanospectra Biosciences, Inc., Cristal Therapeutics, MagArray, Inc. , BlueWillow Biologics, Inc., and many more. #health #healthcare #healthcareindustry #nanomedicine #drugdelivery #targetedtherapy #marketresearch #marketresearchreports #marketanalysis #marketgrowth #industryanalysis #industrygrowth #consulting #marknteladvisors 

'Allo, 'allo, 'allo. What's all this about allogeneic commercial success? Another interesting insight into the challenges allogeneic therapies face vs. their autologous counterparts.